2 citations,
November 2015 in “Journal of Investigative Dermatology Symposium Proceedings” A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.
1 citations,
August 2023 in “Acta dermato-venereologica” Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.
1 citations,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
1 citations,
April 2019 in “Acta Medica Philippina” Azathioprine may help treat severe alopecia areata, but more research is needed.
1 citations,
January 2017 in “SAGE Open Medical Case Reports” A woman's hair loss condition got worse after her varicose vein treatment with a specific foam.
July 2024 in “International Journal of Medical Arts” Latanoprost is more effective than minoxidil for treating alopecia areata.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.
October 2023 in “Dermatology practical & conceptual” Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.
April 2023 in “Medizinische Genetik” New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
TCA injections are more effective and safer than cryotherapy for treating alopecia areata.
January 2021 in “International journal of basic and clinical pharmacology” Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.
August 2017 in “International journal of research in dermatology” 0.05% betamethasone dipropionate is the most effective treatment for mild alopecia areata.
421 citations,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
391 citations,
January 2010 in “Journal of The American Academy of Dermatology” Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.
164 citations,
April 2008 in “Cochrane library” Current treatments for alopecia show no significant long-term benefits.
31 citations,
June 2011 in “Journal of the neurological sciences” Removing the thymoma improved the man's autoimmune conditions.
30 citations,
October 2013 in “Lupus” Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.
22 citations,
June 2013 in “Australasian Journal of Dermatology” Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.
12 citations,
November 1996 in “Australasian journal of dermatology” A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.
11 citations,
November 2021 in “BMJ Open” People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.
9 citations,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
7 citations,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
5 citations,
May 2017 in “Journal of the European Academy of Dermatology and Venereology” The study found no significant difference in stress hormone levels between people with alopecia areata and healthy individuals, suggesting that the disease is not caused by an overactive stress response system.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
2 citations,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
April 2024 in “Proceedings” People with alopecia areata often have lower iron levels than healthy people.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.